Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 2 Mixed models analysis of HLA-DR expression and LPS-induced TNF-ɑ production in 28-day survivors and non-survivors

From: Comparison of monocyte human leukocyte antigen-DR expression and stimulated tumor necrosis factor alpha production as outcome predictors in severe sepsis: a prospective observational study

 

Survivors, n = 58

Non-survivors, n = 25

p

HLA-DR expression (antibodies/cell), median (IQR)

Sample A (days 1–2)a

7495 (4672, 15,824)

n = 51

6971 (2525, 9162)

n = 22

0.14

Sample B (days 3–4)a

11351 (4316, 18,417)

n = 43

5895 (2900, 10,388)

n = 16

0.04

Sample C (days 6–8)a

14470 (7656, 17,906)

n = 18

6195 (3721, 9662)

n = 10

0.002

Δ Sample A to B

434 (-1710, 2921)

-630 (-1795, 626)

0.34

Δ Sample A to C

1662 (-2645, 8118)

810 (-3382, 3507)

0.04

LPS-induced TNF-ɑ production (pg/ml), median (IQR)

Sample A (days 1–2)a

204 (73, 411)

n = 50

176 (80, 396)

n = 22

0.87

Sample B (days 3–4)a

209 (101, 358)

n = 40

232 (106, 716)

n = 16

0.56

Sample C (days 6–8)a

320 (111, 414)

n = 17

225 (29, 358)

n = 10

0.52

Δ Sample A to B

0 (-130, 54)

20 (-23, 89)

0.27

Δ Sample A to C

16 (-112, 85)

29 (-85, 141)

0.56

  1. HLA-DR human leukocyte antigen-DR, LPS lipopolysaccharide, TNF-ɑ tumor necrosis factor alpha, IQR 25 %, 75 % interquartile range
  2. aDays after sepsis diagnosis